{
  "nctId": "NCT03096834",
  "briefTitle": "A Study Evaluating the Effectiveness of AMG 334 Injection in Preventing Migraines in Adults Having Failed Other Therapies",
  "officialTitle": "A 12-week Double-blind, Randomized, Multicenter Study Comparing the Efficacy and Safety of Once Monthly Subcutaneous 140 mg AMG 334 Against Placebo in Adult Episodic Migraine Patients Who Have Failed 2-4 Prophylactic Treatments (LIBERTY)",
  "protocolDocument": {
    "nctId": "NCT03096834",
    "filename": "Prot_000.pdf",
    "label": "Study Protocol",
    "date": "2020-05-22",
    "uploadDate": "2022-01-22T11:53",
    "size": 1037829,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT03096834/document/Prot_000.pdf",
    "hasProtocol": true,
    "hasSap": false,
    "hasIcf": false
  },
  "phase": [
    "PHASE3"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "DOUBLE",
  "enrollmentInfo": {
    "enrollmentCount": 246,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2017-03-20",
    "completionDate": "2021-01-28",
    "primaryCompletionDate": "2018-01-18",
    "firstSubmitDate": "2017-03-17",
    "firstPostDate": "2017-03-30"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Documented history of migraine in the 12 months prior to screen\n* 4-14 days per month of migraine symptoms\n* \\>=80% diary compliance during the Baseline period\n* Failure of previous migraine prophylactic treatments\n\nExclusion Criteria:\n\n* \\>50 years old at migraine onset\n* Pregnant or nursing\n* History of cluster or hemiplegic headache\n* Evidence of seizure or psychiatric disorder\n* Score of over 19 on Beck Depression Inventory-2\n* Active chronic pain syndrome\n* Cardiac or hepatic disease",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": "65 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Percentage of Participants With at Least 50% Reduction From Baseline of Monthly Migraine Days (MMD) in the Last Month (Last 4 Weeks of Treatment)",
        "description": "A migraine day was defined as any calendar day in which the subject experienced a qualified migraine headache defined as: with/without aura, lasting ≥ 30 minutes with at least 1 criteria: 1. ≥ 2 of following pain features: unilateral, throbbing, moderate to severe or exacerbated with exercise/physical activity, 2. ≥ 1 of the following symptoms: nausea and/or vomiting, photophobia and phonophobia. If a migraine-specific medication (ie, triptan or ergotamine) was taken during aura, or a headache, it was counted as a migraine day regardless of duration and pain features/associated symptoms.",
        "timeFrame": "Baseline, Month 3 (last 4 weeks of treatment)"
      }
    ],
    "secondary": [
      {
        "measure": "Change From Baseline in Monthly Migraine Days (MMD) in the Last Month (Last 4 Weeks of Treatment)",
        "description": "A migraine day was defined as any calendar day in which the subject experienced a qualified migraine headache defined as: with/without aura, lasting ≥ 30 minutes with at least 1 criteria: 1. ≥ 2 of following pain features: unilateral, throbbing, moderate to severe or exacerbated with exercise/physical activity, 2. ≥ 1 of the following symptoms: nausea and/or vomiting, photophobia and phonophobia. If a migraine-specific medication (ie, triptan or ergotamine) was taken during aura, or a headache, it was counted as a migraine day regardless of duration and pain features/associated symptoms.",
        "timeFrame": "Baseline, Month 3 (last 4 weeks of treatment)"
      },
      {
        "measure": "Change From Baseline in Physical Impairment and Everyday Activities as Measured by the Migraine Physical Function Impact Diary (MPFID) at Month 3",
        "description": "MPFID has 2 domains: Everyday Activities, which consisted of 7 items and Physical Impairment with 5 items using a 5-point scale. Scores were summed across each domain and were then transformed and used for analyses. Transforming MPFID domain scores ranged from 0-100, where higher scores were indicative of greater migraine impact (ie, higher burden)",
        "timeFrame": "Baseline, Month 3 (last 4 weeks of treatment)"
      },
      {
        "measure": "Change in the Number of Monthly Acute Migraine-specific Medication Treatment Days at Month 3",
        "description": "Number of days on which acute migraine-specific medications were used were recorded in eDiary between each monthly IP dose. Migraine-Specific medications included two categories of medications: triptan-based migraine medications and ergotamine-based migraine medications. Monthly migraine-specific medication use at baseline was the number of migraine-specific medication treatment days in the baseline period.",
        "timeFrame": "Baseline, Month 3 (last 4 weeks of treatment)"
      },
      {
        "measure": "Percentage of Participants With a 75% Reduction From Baseline of Monthly Migraine Days (MMD) in the Last Month (Last 4 Weeks of Treatment)",
        "description": "A migraine day was defined as any calendar day in which the subject experienced a qualified migraine headache defined as: with/without aura, lasting ≥ 30 minutes with at least 1 criteria: 1. ≥ 2 of following pain features: unilateral, throbbing, moderate to severe or exacerbated with exercise/physical activity, 2. ≥ 1 of the following symptoms: nausea and/or vomiting, photophobia and phonophobia. If a migraine-specific medication (ie, triptan or ergotamine) was taken during aura, or a headache, it was counted as a migraine day regardless of duration and pain features/associated symptoms.",
        "timeFrame": "Baseline, Month 3 (last 4 weeks of treatment)"
      },
      {
        "measure": "Percentage of Participants With a 100% Reduction From Baseline of Monthly Migraine Days (MMD) in the Last Month (Last 4 Weeks of Treatment)",
        "description": "A migraine day was defined as any calendar day in which the subject experienced a qualified migraine headache defined as: with/without aura, lasting ≥ 30 minutes with at least 1 criteria: 1. ≥ 2 of following pain features: unilateral, throbbing, moderate to severe or exacerbated with exercise/physical activity, 2. ≥ 1 of the following symptoms: nausea and/or vomiting, photophobia and phonophobia. If a migraine-specific medication (ie, triptan or ergotamine) was taken during aura, or a headache, it was counted as a migraine day regardless of duration and pain features/associated symptoms.",
        "timeFrame": "Baseline, Month 3 (last 4 weeks of treatment)"
      },
      {
        "measure": "Number of Participants Who Developed Anti-AMG334 Antibodies",
        "description": "Blood samples for immunogenicity testing were collected for the measurement of anti-AMG334 binding antibodies.",
        "timeFrame": "Baseline up to approximately 180 weeks"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 6,
      "otherCount": 0,
      "totalCount": 7
    },
    "studyDesign": {
      "phases": [
        "PHASE3"
      ],
      "isRandomized": true,
      "isMasked": true,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 69,
    "complexityCategory": "Complex"
  },
  "collectionDate": "2025-09-22T02:29:52.276Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}